These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23350795)

  • 1. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
    Karl DM; Gill J; Zhou R; Riddle MC
    Diabetes Obes Metab; 2013 Jul; 15(7):622-8. PubMed ID: 23350795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
    Owens DR; Traylor L; Dain MP; Landgraf W
    Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies.
    Riddle MC; Vlajnic A; Zhou R; Rosenstock J
    Diabetes Obes Metab; 2013 Sep; 15(9):819-25. PubMed ID: 23489438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
    Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
    Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial.
    ORIGIN Trial Investigators
    Diabetes Care; 2015 Jan; 38(1):22-8. PubMed ID: 25352653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liberating A1C goals in older adults may not protect against the risk of hypoglycemia.
    Munshi MN; Slyne C; Segal AR; Saul N; Lyons C; Weinger K
    J Diabetes Complications; 2017 Jul; 31(7):1197-1199. PubMed ID: 28343792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR; Traylor L; Mullins P; Landgraf W
    Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V; Gill J; Zhou R; Leahy J
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.